Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) EPS (Basic) (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed EPS (Basic) for 2 consecutive years, with $2.04 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 258.14% to $2.04 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.69, a 63.9% increase, with the full-year FY2025 number at -$0.23, up 98.76% from a year prior.
  • EPS (Basic) was $2.04 for Q4 2025 at Neuphoria Therapeutics, up from -$4.41 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $6.55 in Q1 2025 to a low of -$4.87 in Q2 2025.